North America Colorectal Cancer Market

The colorectal cancer market in North America is expected to grow from US$ 8,559.27 million in 2022 to US$ 11,198.11 million by 2028; it is estimated to grow at a CAGR of 3.4% from 2022 to 2028.

Colorectal cancer is one of the most commonly found lethal cancers in individuals with the combined influence of genetic and environmental factors. A significant population in North America is diagnosed with colorectal cancer. According to the Centers for Disease Control and Prevention (CDC) and the American Cancer Society, an estimated 1.93 million adults in the US were diagnosed with colon and rectum cancer, and 53,200 deaths were caused by colorectal cancer in 2020. These statistics showcase increased demand for advanced cancer diagnostics and therapeutics in the region. Thus, the rising prevalence of colorectal cancer and the rising number of patients diagnosed with the disease are driving the growth of the North America colorectal cancer market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America colorectal cancer market at a substantial CAGR during the forecast period.

North America Colorectal Cancer

Market Revenue and Forecast to 2028 (US$ Million)

North America Colorectal Cancer Strategic Insights

Strategic insights for the North America Colorectal Cancer provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Colorectal Cancer Report Scope

North America Colorectal Cancer Regional Insights

The geographic scope of the North America Colorectal Cancer refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

North America Colorectal Cancer Market Segmentation

The North America colorectal cancer market is segmented into modality, end user, and country. Based on modality, the North America colorectal cancer market is segmented into diagnosis type, therapy type, and imaging type. In 2022, the diagnosis type segment held the largest market share and is expected to register the highest CAGR during the forecast period. Based on end user, the North America colorectal cancer market is bifurcated into hospitals and diagnostic & research laboratories. In 2022, the hospitals segment held a larger market share. Based on country, the North America colorectal cancer market is segmented into the US, Canada, and Mexico. The US held the largest market share in 2022.

Abbott, Amgen Inc., Bruker Corporation, Clinical Genomics Technologies Pty Ltd., Epigenomics AG, F. Hoffmann-La Roche AG, Quest Diagnostics, and VolitionRx Limited are among the leading companies operating in the North America colorectal cancer market.